Axim BIOTECHNOLOGIES, Inc. (AXIM) intrinsic value & 10-year financials
Axim BIOTECHNOLOGIES, Inc. (AXIM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 6.9% a year to $39.5K, with an average return on invested capital of 575.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Revenue (FY2023)
- $39.5K
- Revenue growth (10-yr CAGR)
- -6.9%
- ROIC (10-yr avg)
- 575.9%
- Free cash flow (FY2023)
- -$1.0M
AXIM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2023 | $39.5K | -$8.1M | -$0.04 | -$1.0M | -6961.0% | 44.1% |
| FY2022 | $8.9K | -$6.2M | $0.04 | -$2.1M | -52425.6% | 129.9% |
| FY2021 | $60.5K | -$16.0M | $0.12 | -$2.5M | -23114.5% | 3618.7% |
| FY2020 | — | — | — | — | — | — |
| FY2018 | $195.6K | -$6.8M | — | — | -2574.5% | 63.7% |
| FY2017 | $47.6K | -$4.2M | — | — | -6619.5% | 55.2% |
| FY2016 | $47.1K | -$5.8M | — | -$1.3M | -7988.8% | 122.1% |
| FY2015 | $49.1K | -$10.1M | — | -$1.6M | -20451.3% | 883.1% |
| FY2014 | $0 | -$582.9K | — | -$339.0K | — | 149.9% |
| FY2013 | $75.0K | -$109.0K | — | — | — | 116.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
AXIM BIOTECHNOLOGIES, INC. is facing top-line stagnation, with revenue contracting over the decade.
AXIM BIOTECHNOLOGIES, INC. has earned high returns on invested capital, averaging 80.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
AXIM BIOTECHNOLOGIES, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, AXIM BIOTECHNOLOGIES, INC. is modeled at -6.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.18 per share.